Isoniazid Dose Adjustment According to NAT2 Genotype (IDANAT2)
Gerd Fätkenheuer, Prof. Dr. med.
Abstract
The study is conducted to compare safety and efficacy of isoniazid administered as an adjusted dose based on NAT2 (arylamine N-acetyltransferase type 2)genotype and as a standard dose.
The hypothesis is that the genotype-adjusted dose is superior to the standard dose with regard to hepatotoxicity and early treatment failure, respectively, in the group of slow and rapid acetylators of NAT2.
MeSH terms
- Tuberculosis, Pulmonary